Publikationen in Zusammenarbeit mit Forschern von Fundación Hipercolesterolemia Familiar (35)

2024

  1. Age- and sex-based heterogeneity in coronary artery plaque presence and burden in familial hypercholesterolemia: A multi-national study

    American Journal of Preventive Cardiology, Vol. 17

  2. Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT Study

    Circulation. Cardiovascular imaging, Vol. 17, Núm. 1, pp. e016206

  3. Circulating miR-6821-5p levels and coronary calcification in asymptomatic familial hypercholesterolemia patients

    Atherosclerosis, Vol. 392

2023

  1. Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study

    Circulation, Vol. 147, Núm. 19, pp. 1436-1443

  2. Persistence with long-term PCSK9 inhibitor treatment and its effectiveness in familial hypercholesterolaemia: data from the SAFEHEART study

    European journal of preventive cardiology, Vol. 30, Núm. 4, pp. 320-328

  3. Response by Pérez de Isla et al to Letter Regarding Article, "Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients With Familial Hypercholesterolemia: The ARCHITECT Study"

    Circulation

2022

  1. A resilient type of familial hypercholesterolaemia: case-control follow-up of genetically characterized older patients in the SAFEHEART cohort

    European Journal of Preventive Cardiology, Vol. 29, Núm. 5, pp. 795-801

  2. Predicting resilience in heterozygous familial hypercholesterolaemia: A cohort study of octogenarian patients

    Journal of Clinical Lipidology, Vol. 16, Núm. 5, pp. 733-736

  3. Relationship between the coronary artery calcium quantification and gut microbiota composition in subjects without previous cardiovascular disease: A pilot study

    Clinica e Investigacion en Arteriosclerosis, Vol. 34, Núm. 4, pp. 205-215

2021

  1. Coronary plaque burden, plaque characterization and their prognostic implications in familial hypercholesterolemia: A computed tomographic angiography study

    Atherosclerosis, Vol. 317, pp. 52-58

  2. Dyslipidemia and aortic valve disease

    Current opinion in lipidology, Vol. 32, Núm. 6, pp. 349-354

  3. Lipoprotein(a), LDL-cholesterol, and hypertension: Predictors of the need for aortic valve replacement in familial hypercholesterolaemia

    European Heart Journal, Vol. 42, Núm. 22, pp. 2201-2211

  4. The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia

    JACC: Cardiovascular Imaging, Vol. 14, Núm. 12, pp. 2414-2424

2020

  1. Heart failure and diabetes, opportunities for improving treatment through patient characterisation

    Revista Clinica Espanola

  2. Incidence of cardiovascular events and changes in the estimated risk and treatment of familial hypercholesterolemia: the SAFEHEART registry

    Revista Espanola de Cardiologia, Vol. 73, Núm. 10, pp. 828-834

2019

  1. Liquid Biopsy of Extracellular Microvesicles Maps Coronary Calcification and Atherosclerotic Plaque in Asymptomatic Patients with Familial Hypercholesterolemia: A Computed Tomographic Angiography Imaging Study

    Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 39, Núm. 5, pp. 945-955

  2. Long-term effect of 2 intensive statin regimens on treatment and incidence of cardiovascular events in familial hypercholesterolemia: The SAFEHEART study

    Journal of Clinical Lipidology, Vol. 13, Núm. 6, pp. 989-996

  3. Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia

    Atherosclerosis, Vol. 286, pp. 40-45

  4. VEGFR2 and OPG genes modify the risk of subclinical coronary atherosclerosis in patients with familial hypercholesterolemia

    Atherosclerosis, Vol. 285, pp. 17-22

  5. Value of Measuring Lipoprotein(a) During Cascade Testing for Familial Hypercholesterolemia

    Journal of the American College of Cardiology, Vol. 73, Núm. 9, pp. 1029-1039